Evidence map›Paper›PMID 32926822›Full record

ArticleAnnals of internal medicine2020

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.

Rochelle P Walensky, Tim Horn, Nicole C McCann, Kenneth A Freedberg, A David Paltiel

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Rochelle P WalenskyMedical Practice Evaluation Center, Massachusetts General Hospital, Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (R.P.W.).
Tim HornNational Alliance of State and Territorial AIDS Directors, Washington, DC (T.H.).
Nicole C McCannMassachusetts General Hospital, Boston, Massachusetts (N.C.M.).
Kenneth A FreedbergMassachusetts General Hospital and Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts (K.A.F.).
A David PaltielYale School of Public Health, New Haven, Connecticut (A.D.P.).ORCID 0000-0002-4861-3290

Funding

Development and application of a new simulation model for COVID-19R01AI042006 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Anne Neilan · 1998 to 2026
$12.9M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
Novel approaches to the design and evaluation of combination HIV preventionR01MH105203 · NIMH · YALE UNIVERSITY · PI PALTIEL, A. DAVID · 2014 to 2018
$3.3M
NIAID NIH HHS R01 AI042006NIDA NIH HHS R37 DA015612NIMH NIH HHS R01 MH105203
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisAdenineAlanineCost-Benefit AnalysisEmtricitabineFamilyHumansTenofovirAdenineAlanineEmtricitabineTenofovirtenofovir alafenamide

Identifiers

PMID32926822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.